人彌漫性大B細(xì)胞淋巴瘤細(xì)胞WSU-DLCL2

細(xì)胞名稱

人彌漫性大B細(xì)胞淋巴瘤細(xì)胞WSU-DLCL2

貨物編碼

BFN60807366

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細(xì)胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運(yùn)輸方式

常溫保溫運(yùn)輸

干冰運(yùn)輸

安全等級(jí)

1

用途限制

僅供科研           2類

培養(yǎng)體系

DMEM高糖培養(yǎng)基+10%FBS+1%三抗 

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人彌漫性大B細(xì)胞淋巴瘤細(xì)胞WSU-DLCL2取自41歲男性供體。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: TCGA-110-CL cell line panel.

Doubling time: 18 hours (PubMed=9607591); ~50-70 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Omics: Virome analysis using RNAseq.

Misspelling: WSU-DCL2; In GEO GSM1374991.

Derived from sampling site: Pleural effusion.

基因突變

Heterozygous for EZH2 p.Tyr646Phe (c.1937A>T) (Y641F) (CCLE; Cosmic-CLP).

Homozygous for TP53 p.Arg248Gln (c.743G>A) (CCLE; Cosmic-CLP).

HLA信息

Class I

HLA-A        A*24/29

HLA-C        C*12/15

STR信息

Amelogenin        X,Y

CSF1PO        11

D3S1358        14,16

D5S818        11,12

D7S820        10,12

D8S1179        12,13

D13S317        11,14

D16S539        10,13

D18S51        15,16

D21S11        29,32.2

FGA        22

Penta D        10,13

Penta E        14,19

TH01        8,9

TPOX        8

vWA        16,17

參考文獻(xiàn)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574-3574(2019)